ClinicalTrials.gg
CompletedNCT01204593SUBSTITUTEUpdated Mar 17, 2014

baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus

A Phase 4 interventional study of INSULIN GLARGINE and INSULIN GLULISINE in Diabetes Mellitus, Type 1, sponsored by Sanofi. Completed at 43 sites in 9 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-03-17.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
206
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Enrollment
19th of 66
206 · median 73
Started
2010
with 2 others
Phase 4
24 of 66
none open now
Registered
25th of 66
by date
Lead sponsor
24 of 66
Sanofi

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 19th largest by enrollment, is one of 3 that started in 2010, is one of 24 in phase 4, and was the 25th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of the association Lantus (once-a-day, od) Apidra (thrice-a-day, tid) in terms of change HbA1c from baseline to end of study (week 24), in patients with Type 1 Diabetes Mellitus (T1DM).

Secondary Objectives:

To evaluate:

  • The change of hemoglobin A1c (HbA1c) from baseline to week 12
  • The percentage of patients with HbA1c \< 7% at week 12 and week 24
  • The FBG and the 7-point self monitoring of blood glucose (SMBG) at baseline, week 12 and week 24
  • The daily dose for both insulin glulisine insulin glargine at baseline, week 12 and week 24
  • The incidence of symptomatic hypoglycemias
  • Adverse events
Read the detailed description

After a two-week run-in period patients will enter a six-month treatment period.

Estimated study duration per patient : 26 weeks (including a 2-week run-in period).

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Known Type 1 diabetic patients (male or female) treated with any type of insulin regimen, except:

    • continuous subcutaneous insulin infusion (CSII, or pump), and
    • patients already treated with insulin glargine
  2. Age: 18-60 years inclusive
  3. : 8% - 10% assessed over the past 6 month
  4. At least 1 year of continuous insulin treatment
  5. Willingness to accept, and ability to follow:

    • a basal bolus regimen (glargine x1 and glulisine x3 per day),
    • self-monitoring blood glucose (SMBG)
    • a fixed meal plan, or CHO counting
  6. Signed obtained prior to any study procedure

Criteria for entry in the treatment period:

  1. HbA1c 8-10% assessed between week -2 and week 0
  2. Serum creatinine ≤135 micromol/L in men and ≤110 micromol/L in women
  3. (ALT) and/or Aspartate aminotransferase (AST) lower or equal to three times the
  4. Pregnancy test negative if women of

Exclusion criteria

Exclusion criteria:

  1. History of to insulin glargine and/or insulin glulisine
  2. Pregnant, breast-feeding or women of not using efficient
  3. Brittle diabetes
  4. Known impaired renal function defined as serum creatinine > 135 micromol/L in men and > 110 micromol/L in women at study entry
  5. Known impaired hepatic function defined as (ALT) and/or Aspartate aminotransferase (AST) greater than three times the at study entry
  6. Diabetes ketoacidosis
  7. History of drug or alcohol abuse
  8. Psychiatric or mental disease
  9. Inclusion in another study in the past 6 months or previous inclusion in this study
  10. Patient unable or unwilling to manage properly the basal bolus regimen

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    Insulin glargine + insulin glulisine

    Insulin glargine dosage will be individually titrated once a week to obtain FPG 80-120 mg/dL (4.5-6.7 mmol/L). Insulin glulisine dosage will be individually titrated once a week to obtain a 2-hour postprandial plasma glucose (PPG) \< 180 mg/dL (\<10.0 mmol/L) and ideally around 140 mg/dL.

    Drug: INSULIN GLARGINE · Drug: INSULIN GLULISINE

Interventions

  • Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime

    Also known as: Lantus SoloStar

  • Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal

    Also known as: Apidra SoloStar

06

What researchers measure

Primary outcomes

  1. Change in hemoglobin A1c (HbA1c) values (following the reference of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC))

    Time frame: between baseline (week 0) and endpoint (week 24)

Secondary outcomes

  1. Change of HbA1c

    Time frame: from baseline to week 12

  2. Percentage of patients with HbA1c < 7%

    Time frame: at week 12 and week 24

  3. Fasting Blood Glucose (FBG)

    Time frame: at baseline, week 12 and week 24

  4. 7-point Self Monitoring of Blood Glucose (SMBG)

    Time frame: at baseline, week 12 and week 24 (to be performed the week preceding each visit on two consecutive days)

  5. Daily dose for insulin glulisine

    Time frame: At baseline, week 12 and week 24

  6. Daily dose for insulin glargine

    Time frame: At baseline, week 12 and week 24

  7. Symptomatic hypoglycemias

    Time frame: From baseline (week 0) to endpoint (week 24)

07

Study locations

43 sites
  • Investigational Site Number 01201
    Algeries, Algeria
  • Investigational Site Number 01202
    Algiers, Algeria
  • Investigational Site Number 01203
    Algiers, Algeria
  • Investigational Site Number 01204
    Algiers, Algeria
  • Investigational Site Number 03201
    Caba, Argentina
  • Investigational Site Number 03202
    Caba, Argentina
  • Investigational Site Number 03203
    Caba, Argentina
  • Investigational Site Number 03204
    Caba, Argentina
  • Investigational Site Number 03205
    Morón, Argentina
  • Investigational Site Number 076-007
    Curitiba, 80540-010, Brazil
  • Investigational Site Number 076-003
    Distrito Federal, 71625-009, Brazil
  • Investigational Site Number 076-010
    Fortaleza, 60430-370, Brazil
  • Investigational Site Number 076-006
    Marília, 17519-101, Brazil
  • Investigational Site Number 076-004
    Porto Alegre, 91350-250, Brazil
  • Investigational Site Number 076-002
    São Paulo, 01244-030, Brazil
  • Investigational Site Number 17003
    Barranquilla, Colombia
  • Investigational Site Number 17004
    Bogotá, Colombia
  • Investigational Site Number 17005
    Bogotá, Colombia
  • Investigational Site Number 17007
    Bogotá, Colombia
  • Investigational Site Number 17006
    Medellin, Colombia
  • Investigational Site Number 01
    Kuwait, Kuwait
  • Investigational Site Number 48401
    Guadalajara, 44600, Mexico
  • Investigational Site Number 48402
    Guadalajara, 44656, Mexico
  • Investigational Site Number 48404
    Guadalajara, 44680, Mexico
  • Investigational Site Number 48403
    Monterrey, 64460, Mexico
  • Investigational Site Number 1
    Riyadh, 11415, Saudi Arabia
  • Investigational Site Number 12468
    Benoni, South Africa
  • Investigational Site Number 710004
    Benoni, South Africa
  • Investigational Site Number 12466
    Bloemfontein, 9301, South Africa
  • Investigational Site Number 710006
    Bloemfontein, 9301, South Africa
  • Investigational Site Number 12464
    Durban, 4091, South Africa
  • Investigational Site Number 12465
    Durban, 4091, South Africa
  • Investigational Site Number 710001
    Durban, 4091, South Africa
  • Investigational Site Number 710002
    Durban, 4091, South Africa
  • Investigational Site Number 12484
    Port Elizabeth, 6000, South Africa
  • Investigational Site Number 710003
    Port Elizabeth, 6000, South Africa
  • Investigational Site Number 12467
    Pretoria, South Africa
  • Investigational Site Number 710005
    Pretoria, South Africa
  • Investigational Site Number 78801
    Sfax, Tunisia
  • Investigational Site Number 78805
    Sfax, Tunisia
  • Investigational Site Number 78803
    Tunis, 1006, Tunisia
  • Investigational Site Number 78802
    Tunis, Tunisia
  • Investigational Site Number 78804
    Tunis, Tunisia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2010
First posted
Sep 17, 2010
Start
Nov 2010
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Last update
Mar 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01204593
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 17, 2010
Start date
Nov 2010
Primary completion
Jan 2013
Completion
Jan 2013
Last update
Mar 17, 2014

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Insulin glulisine

Start the discussion